“We have brought together the leading scientists in the field as active colleagues to create a new and powerful force in stem cell science. Drs. Daley, Srivastava, Melton and Rubin share our conviction that together we can create a paradigm shift in the way drug discovery and the development of new therapeutics is conducted by pharmaceutical companies throughout the world.”
-iPierian CEO John Walker
George Q. Daley, MD, PhD
Scientific co-founder and co-chair of the scientific advisory board of iPierian Inc.; Samuel E. Lux IV Professor of Hematology and Director of the Stem Cell Transplantation Program at Children’s Hospital Boston; Professor of Biological Chemistry and Molecular Pharmacology and Pediatrics at Harvard Medical School and an investigator of the Howard Hughes Medical Institute more
Dr. Deepak Srivastava, MD
Scientific co-founder and co-chair of the scientific advisory board of iPierian Inc.; Director of the Gladstone Institute of Cardiovascular Disease, and professor of Pediatrics and Biochemistry and Biophysics and Wilma and Adeline Pirag Distinguished Professor in Pediatric Developmental Cardiology at the University of California, San Francisco more
Douglas A. Melton, PhD
Scientific co-founder and member of the scientific advisory board of iPierian Inc., Co-director of the Harvard Stem Cell Institute and Thomas Dudley Cabot Professor in the Natural Sciences at Harvard University, and Howard Hughes Medical Institute Investigator more
Lee Rubin, PhD
Scientific co-founder and member of the scientific advisory board of iPierian Inc. and Director of Translational Medicine, Harvard Stem Cell Institute more
Cellular reprogramming; including the differentiation of disease‐relevant induced pluripotent stem cells (iPSC) represents the fastest and most promising means of transforming drug discovery and ushering in a new era of therapeutics discovered using actual patient cells as the basis of discovery. This breakthrough provides additional hope for patients with a multitude of diseases, especially neurological and metabolic diseases where iPierian is concentrating its research and development activities.
To accelerate the application of iPS technology to the drug discovery and development process, iPierian has built one of the most qualified teams of stem cell scientists in the world. Our internationally-renowned scientific founders include leaders of the Harvard Stem Cell Institute and the Gladstone Institute, whose diverse professional expertise support our goals at iPierian. Drs. George Daley, Douglas Melton and Lee Rubin, who are also faculty members at Harvard University, and Dr. Deepak Srivastava, a faculty member at University of California, San Francisco, are actively involved in decisions regarding the scientific direction and research priorities for iPierian. The overarching goal of our scientific advisors is to translate academic achievements in stem cell research into disease‐relevant technologies for drug discovery and ultimately new regenerative therapies to help patients with a broad range of diseases.